Search Results
When should patients with intermediate-risk AML be indicated for alloSCT?
The role of allogeneic transplantation in patients with AML in the frontline setting
MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSM
Treatment of intermediate-risk AML with gemtuzumab ozogamicin
Predicting the outcomes of patients with AML treated with CPX-351 based on ELN risk stratification
Determining the most suitable consolidation therapies for AML by defining patient risk group
Indications for stem cell transplantation for patients with AML
Optimising transplant outcome in adults allografted for AML
The impact of cytogenetic-risk stratification on AML outcomes
AML Indications for Transplantation and Treatment of Relapse
Debate: How should IPSS-R intermediate risk MDS be approached? - As higher risk disease
Transplant indications in AML
